BlackRock Health Sciences Opportunities Port Inst (SHSSX)
65.28
+1.07
(+1.67%)
USD |
May 16 2025
Key Stats
Customize
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 0.84% | 6.523B | 1.09% | 27.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -1.409B | -6.70% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term growth of capital. Under normal market conditions, the Fund invests at least 80% of total assets in equity securities, primarily common stock, of companies in health sciences and related industries. The Fund reserves the right to invest up to 20% of its total assets in other types of securities. |
| General | |
| Security Type | Mutual Fund |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | BlackRock |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
88
-403.39M
Peer Group Low
5.622M
Peer Group High
1 Year
% Rank:
95
-1.409B
-2.387B
Peer Group Low
38.72M
Peer Group High
3 Months
% Rank:
90
-1.086B
Peer Group Low
14.69M
Peer Group High
3 Years
% Rank:
97
-5.439B
Peer Group Low
100.98M
Peer Group High
6 Months
% Rank:
94
-1.863B
Peer Group Low
11.03M
Peer Group High
5 Years
% Rank:
98
-6.179B
Peer Group Low
5.011B
Peer Group High
YTD
% Rank:
94
-949.16M
Peer Group Low
13.77M
Peer Group High
10 Years
% Rank:
96
-11.45B
Peer Group Low
5.592B
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of May 17, 2025.
Asset Allocation
As of October 31, 2024.
| Type | % Net |
|---|---|
| Cash | 0.29% |
| Stock | 98.84% |
| Bond | 0.78% |
| Convertible | 0.00% |
| Preferred | 0.08% |
| Other | 0.00% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Eli Lilly and Co | 8.02% | 757.39 | 3.29% |
| AbbVie Inc | 6.90% | 184.02 | 1.29% |
| Boston Scientific Corp | 5.43% | 106.04 | 1.13% |
| UnitedHealth Group Inc | 5.25% | 291.91 | 6.40% |
| Abbott Laboratories | 4.78% | 134.80 | 1.09% |
| Thermo Fisher Scientific Inc | 3.55% | 412.06 | 1.76% |
| Stryker Corp | 3.49% | 394.21 | 0.51% |
| Johnson & Johnson | 3.01% | 151.33 | 1.15% |
| Amgen Inc | 2.99% | 272.41 | 0.26% |
| Gilead Sciences Inc | 2.98% | 102.50 | 2.15% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | -- |
| Actual Management Fee | 0.67% |
| Administration Fee | 2.38M% |
| Maximum Front Load | -- |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | 0.00% |
| General Availability | |
| Available for Insurance Product | -- |
| Available for RRSP | -- |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 2.00M None |
| Minimum Subsequent Investment | 0.00 None |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term growth of capital. Under normal market conditions, the Fund invests at least 80% of total assets in equity securities, primarily common stock, of companies in health sciences and related industries. The Fund reserves the right to invest up to 20% of its total assets in other types of securities. |
| General | |
| Security Type | Mutual Fund |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | BlackRock |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (5-16-25) | 0.39% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Stock | |
| Weighted Average PE Ratio | 42.84 |
| Weighted Average Price to Sales Ratio | 8.795 |
| Weighted Average Price to Book Ratio | 10.20 |
| Weighted Median ROE | 26.94% |
| Weighted Median ROA | 3.47% |
| ROI (TTM) | 6.31% |
| Return on Investment (TTM) | 6.31% |
| Earning Yield | 0.0281 |
| LT Debt / Shareholders Equity | 1.796 |
As of October 31, 2024
Growth Metrics
| EPS Growth (1Y) | 6.64% |
| EPS Growth (3Y) | 8.65% |
| EPS Growth (5Y) | 8.67% |
| Sales Growth (1Y) | 11.39% |
| Sales Growth (3Y) | 13.66% |
| Sales Growth (5Y) | 14.82% |
| Sales per Share Growth (1Y) | 15.67% |
| Sales per Share Growth (3Y) | 16.91% |
| Operating Cash Flow - Growth Ratge (3Y) | 3.01% |
As of October 31, 2024
Fund Details
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:SHSSX", "name") |
| Broad Asset Class: =YCI("M:SHSSX", "broad_asset_class") |
| Broad Category: =YCI("M:SHSSX", "broad_category_group") |
| Prospectus Objective: =YCI("M:SHSSX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |